MA49396B1 - Traitement de la migraine avec acétyl-leucine - Google Patents

Traitement de la migraine avec acétyl-leucine

Info

Publication number
MA49396B1
MA49396B1 MA49396A MA49396A MA49396B1 MA 49396 B1 MA49396 B1 MA 49396B1 MA 49396 A MA49396 A MA 49396A MA 49396 A MA49396 A MA 49396A MA 49396 B1 MA49396 B1 MA 49396B1
Authority
MA
Morocco
Prior art keywords
leucine
migraine
acetyl
treatment
subject
Prior art date
Application number
MA49396A
Other languages
English (en)
French (fr)
Other versions
MA49396A (fr
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49396(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA49396A publication Critical patent/MA49396A/fr
Publication of MA49396B1 publication Critical patent/MA49396B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49396A 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine MA49396B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (2)

Publication Number Publication Date
MA49396A MA49396A (fr) 2020-04-22
MA49396B1 true MA49396B1 (fr) 2021-03-31

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49396A MA49396B1 (fr) 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine

Country Status (25)

Country Link
US (1) US11471434B2 (enExample)
EP (1) EP3638370B1 (enExample)
JP (1) JP7130739B2 (enExample)
KR (1) KR102594130B1 (enExample)
CN (1) CN111093772B (enExample)
AU (1) AU2018284330B2 (enExample)
CY (1) CY1123860T1 (enExample)
DK (1) DK3638370T3 (enExample)
ES (1) ES2847169T3 (enExample)
GB (1) GB201709459D0 (enExample)
HR (1) HRP20210108T1 (enExample)
HU (1) HUE053089T2 (enExample)
IL (1) IL271211B2 (enExample)
LT (1) LT3638370T (enExample)
MA (1) MA49396B1 (enExample)
MD (1) MD3638370T2 (enExample)
MX (1) MX387909B (enExample)
PL (1) PL3638370T3 (enExample)
PT (1) PT3638370T (enExample)
RS (1) RS61481B1 (enExample)
SG (1) SG11201912146RA (enExample)
SI (1) SI3638370T1 (enExample)
SM (1) SMT202100037T1 (enExample)
WO (1) WO2018229738A1 (enExample)
ZA (1) ZA201908087B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221886B2 (en) * 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1641775B1 (en) * 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
CN1856484B (zh) * 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
JP4634385B2 (ja) * 2003-09-22 2011-02-16 ユーロ−セルティーク エス.エイ. 疼痛の治療に有用なフェニル−カルボキサミド化合物
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004019576D1 (de) * 2003-12-30 2009-04-02 Euro Celtique Sa Zur behandlung von schmerzen geeignete piperazine
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5876423B2 (ja) * 2010-06-22 2016-03-02 塩野義製薬株式会社 Trpv1阻害活性を有する化合物とその使用
EP3103469B1 (en) 2010-06-25 2020-12-09 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
ES2732818T3 (es) * 2010-11-09 2019-11-26 Mannkind Corp Composición que comprende un agonista de receptores de serotonina y una dicetopiperazina para tratar migrañas
WO2013021276A1 (en) * 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
MA43876B1 (fr) 2016-08-11 2019-04-30 Intrabio Ltd Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
LT3600276T (lt) 2017-03-28 2023-08-10 Intrabio Ltd Betahistinas arba farmaciniu požiūriu priimtina jo druska ir monoaminooksidazės inhibitorius, skirti panaudoti subjekto gydymui arba profilaktikai vieno arba daugiau vestibulinio galvos svaigimo simptomų
RU2763425C2 (ru) 2017-10-18 2021-12-29 Интрабио Лимитед Терапевтические агенты для нейродегенеративных заболеваний
WO2019079536A1 (en) 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS
AU2019221886B2 (en) 2018-02-15 2024-08-08 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
SI3934637T1 (sl) 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
PL3989962T3 (pl) 2019-06-28 2025-11-17 Intrabio Ltd Terapia skojarzona acetyloleucyną i miglustatem w leczeniu lizosomalnej choroby spichrzeniowej
US20230051742A1 (en) 2020-01-13 2023-02-16 Intrabio Ltd. Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
PL3638370T3 (pl) 2021-05-17
KR20210013518A (ko) 2021-02-04
SMT202100037T1 (it) 2021-03-15
ES2847169T3 (es) 2021-08-02
DK3638370T3 (da) 2021-01-25
US20200253905A1 (en) 2020-08-13
CN111093772A (zh) 2020-05-01
CN111093772B (zh) 2023-11-03
ZA201908087B (en) 2024-11-27
SI3638370T1 (sl) 2021-04-30
CY1123860T1 (el) 2022-05-27
WO2018229738A1 (en) 2018-12-20
AU2018284330B2 (en) 2024-03-14
IL271211B1 (en) 2023-09-01
RU2020100475A (ru) 2021-07-14
KR102594130B1 (ko) 2023-10-24
JP7130739B2 (ja) 2022-09-05
CA3067321A1 (en) 2018-12-20
MD3638370T2 (ro) 2021-04-30
HRP20210108T1 (hr) 2021-03-19
EP3638370B1 (en) 2020-11-11
EP3638370A1 (en) 2020-04-22
JP2020526575A (ja) 2020-08-31
US11471434B2 (en) 2022-10-18
BR112019026660A2 (pt) 2020-07-14
MX387909B (es) 2025-03-19
MA49396A (fr) 2020-04-22
RU2020100475A3 (enExample) 2021-10-22
MX2019014784A (es) 2021-11-16
AU2018284330A1 (en) 2020-01-02
HUE053089T2 (hu) 2021-06-28
SG11201912146RA (en) 2020-01-30
PT3638370T (pt) 2021-01-26
RS61481B1 (sr) 2021-03-31
LT3638370T (lt) 2021-03-25
GB201709459D0 (en) 2017-07-26
IL271211B2 (en) 2024-01-01
IL271211A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA43468A1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MA35156B1 (fr) 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
FR3032883B1 (fr) Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
ZA201901370B (en) Formulations for oral administration of active agents
MA55199B1 (fr) (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA49396A (fr) Traitement de la migraine avec acétyl-leucine
TN2010000108A1 (fr) Traitement de symtomes vasomoteurs
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA33090B1 (fr) Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
MA54511B1 (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MA44769B1 (fr) Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques
MA41668A1 (fr) Composition multi-pertidique